QRG Capital Management Inc. Has $9.48 Million Holdings in Pfizer Inc. (NYSE:PFE)

QRG Capital Management Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 357,479 shares of the biopharmaceutical company’s stock after selling 47,576 shares during the period. QRG Capital Management Inc.’s holdings in Pfizer were worth $9,484,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Versor Investments LP acquired a new position in shares of Pfizer during the 4th quarter worth about $570,000. First Command Advisory Services Inc. grew its holdings in Pfizer by 2.5% during the fourth quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 418 shares during the period. Proficio Capital Partners LLC increased its position in Pfizer by 2,193.2% during the fourth quarter. Proficio Capital Partners LLC now owns 225,584 shares of the biopharmaceutical company’s stock worth $5,985,000 after buying an additional 215,747 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in Pfizer by 2.1% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 2,230,300 shares of the biopharmaceutical company’s stock valued at $59,170,000 after buying an additional 46,200 shares during the period. Finally, New York Life Investment Management LLC lifted its position in shares of Pfizer by 1.2% in the fourth quarter. New York Life Investment Management LLC now owns 786,520 shares of the biopharmaceutical company’s stock valued at $20,866,000 after buying an additional 9,007 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Pfizer stock opened at $26.09 on Friday. The stock’s fifty day moving average price is $26.35 and its two-hundred day moving average price is $27.35. The firm has a market cap of $147.83 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Finally, Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.